 The primary objective is to assess the dose-response relationship of SL77.0499 10 alfuzosin hydrochloride 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with lower urinary tract symptoms LUTS related to BPH. 